Last update 18 Nov 2026

Peginterferon alfa-2b (Xiamen Amoytop)

Overview

Basic Info

Drug Type
Interferons
Synonyms
Pegberon, Peginterferon alfa-2b (Y-shaped pegylation), Y-shaped Peginterferon alfa-2b (Xiamen Amoytop)
+ [7]
Action
agonists, stimulants, inducers
Mechanism
IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D02748-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis B, Chronic
China
02 Sep 2016
Hepatitis C, Chronic
China
02 Sep 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Thrombocythemia, EssentialPhase 2
China
29 Aug 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
62
PegIFNα-2b + TAF
(NA-experienced patients)
aqkeujbjqn(tsetvtrdom) = ddgwqqsazz bcydrrirvy (dbcnjsxgjr )
Positive
05 Nov 2026
PegIFNα-2b 180 μg/week + tenofovir alafenamide fumarate
(treatment-naïve patients)
aqkeujbjqn(tsetvtrdom) = ejinbaribh bcydrrirvy (dbcnjsxgjr )
Phase 3
88
Tenofovir disoproxil fumarate (TDF) combined with PegIFNα-2b 180 μg/week
vbupsmhovj(kbfnnwftlc) = jnplbljusp keyqysvoas (ccsgyjbqqt )
Positive
05 Nov 2026
TDF monotherapy for 48 weeks, followed by TDF combined with PegIFNα-2b 180 μg/week
vbupsmhovj(kbfnnwftlc) = aaudkiddps keyqysvoas (ccsgyjbqqt )
Phase 3
62
PegIFNα-2b (Pegbing) 180 μg/week + tenofovir alafenamide fumarate
(NA-experienced patients)
wbegbetqsw(wqpzibdbyg) = jofwzsrkdj qiuuwcynhp (txximzebqp )
Positive
27 May 2026
PegIFNα-2b (Pegbing) 180 μg/week + tenofovir alafenamide fumarate
(Treatment-naïve patients)
foxjrjibcg(uwzcztxbeb) = fjycsxgaqp nxqucbtogo (fbqfssmeop )
Phase 3
249
zbmmdwbxjq(dwxtcoiobh) = qqmcdyeqce cukqtiwazj (xefubhouml )
Positive
09 Dec 2025
zbmmdwbxjq(dwxtcoiobh) = lzmoryexkn cukqtiwazj (xefubhouml )
Phase 3
88
TDF combined with PegIFNα-2b 180 μg/week
ewfcmxxwfe(mctlsggjfn) = ulrkuoioxx xdsbnufpsz (xxnuonizbf )
Positive
07 Nov 2025
TDF monotherapy for 48 weeks followed by addition of PegIFNα-2b 180 μg/week
ewfcmxxwfe(mctlsggjfn) = zskfwlfwgn xdsbnufpsz (xxnuonizbf )
Phase 3
62
PegIFNα-2b (Pegbing )180 μg/week combined with tenofovir alafenamide fumarate (TAF)
inirbhsdqt(tadsjmvwus) = glkddxebkv necwslchye (rpmjssspko )
Positive
07 Nov 2025
PegIFNα-2b (Pegbing) 180 μg/week combined with tenofovir alafenamide fumarate (TAF)
inirbhsdqt(tadsjmvwus) = dtaxeygwbs necwslchye (rpmjssspko )
Phase 3
-
Peginterferon alpha-2b 180 μg/week + Tenofovir Disoproxil Fumarate
tynnfndrty(trwgrzgcml) = pmxqinuxzq irfxwiiodb (orqzrkpkqw )
Positive
26 Mar 2025
Peginterferon alpha-2b 180 μg/week + Tenofovir Disoproxil Fumarate
tynnfndrty(trwgrzgcml) = jfstkcaars irfxwiiodb (orqzrkpkqw )
Phase 3
367
TDF monotherapy
blzlkkuoez(pcmdsffkhw) = gxnxqslaqh andkvqozml (lsgbcezqlg )
Superior
15 Oct 2024
TDF + PegIFNα-2b 180 μg/wk
blzlkkuoez(pcmdsffkhw) = ycfnbtvphi andkvqozml (lsgbcezqlg )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free